by neville@docmode.com | Jul 12, 2023
The FDA has authorized the humanized monoclonal antibody lecanemab (Leqembi; Eisai) as a therapy for early Alzheimer’s disease (AD). In the last 20 years, it has been FDA-approved twice, but this is the first time through a conventional route. Lecanemab provided...
by neville@docmode.com | Jul 10, 2023
A retrospective evaluation was done to evaluate the impact of gastroenterology (GI) consultation on clinical outcomes in patients hospitalized with hepatic encephalopathy (HE). The study involved 425 individuals hospitalized to a tertiary care hospital between January...
by neville@docmode.com | Jul 10, 2023
The complicated world of neonatal herpes simplex virus (HSV) infection and its effects on the central nervous system (CNS) are explored in this article. The article includes three cases to illustrate the various clinical traits and results connected to CNS involvement...
by neville@docmode.com | Jul 7, 2023
The Duke Neurology Department has made significant contributions to the field with 15 peer-reviewed journal articles in June. These articles highlight groundbreaking therapies for brain tumors and the validation of a stroke treatment for patients taking vitamin K...
by neville@docmode.com | Jul 5, 2023
Myasthenia Gravis (MG) is an autoimmune disease caused by the activation of the complement system. Complement-targeting treatments, such as anti-C1q and anti-C6 antibodies, have shown promise in inhibiting complement-mediated destruction and improving the lives of MG...
